Skip to content
DataLookout
Menu

SERENITYNCT07760818

A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)

StatusRecruiting
PhasePhase 2
Sponsorargenx
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Aug 14, 2026 to Oct 9, 2026
    • Secondary endpoints: details revised at 10 of 13 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A
Timeframe: Up to 48 weeks

Secondary (13)

Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score over time
Change from baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at the end of part A and over time
Change from baseline in clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) score at the end of part A and over time
Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at the end of part A and over time
Proportion of participants with low disease activity (clinESSDAI < 5) at the end of part A and over time
Show 8 moreShow less
Incidence of AEs
Change from baseline in Neuropathic Pain Questionnaire (NPQ) at the end of part A and over time
Change from baseline in the Difficulty Thinking Numerical Rating Scale (NRS) at the end of part A and over time
Change from baseline in Patient Global Impression of Severity (PGIS) scores at the end of part A and over time
Change from baseline in Patient Global Impression of Change (PGIC) scores at the end of part A and over time
Change from baseline in Clinical Global Impression of Severity (CGIS) scores at the end of part A and over time
Change from baseline in Clinical Global Impression of Change (CGIC) scores at the end of part A and over time
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scores at the end of part A and over time

Arms and interventions

Double-blinded treatment period (DBTP): Efgartigimod PH20 SCExperimental

Participants receiving efgartigimod PH20 SC during the double-blinded treatment period

Double-blinded treatment period (DBTP): Placebo PH20 SCPlacebo comparator

Participants receiving placebo PH20 SC during the double-blinded treatment period

Open-label treatment period (OLTP)Experimental

Participants receiving efgartigimod PH20 SC during the open-label treatment period

Biologicals: efgartigimod PH20 SC

Other: Placebo PH20 SC

Sites

3 sites in 1 country